SeekingAlpha · Nov 10, 2026
Tandem Diabetes Care, Inc. 2026 Q3 - Results - Earnings Call Presentation
2026-11-10. The following slide deck was published by Tandem Diabetes Care, Inc.
TN
NASDAQ · TNDM
Tandem Diabetes Care, Inc.
Healthcare · Medical - Devices
$20.07
Up+$2.56 (+14.62%)
Updated Nov 15, 2026, 4:06 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.42B
- P/E ratio
- -6.98
- Dividend yield
- 0.00%
- 52-week range
- $12.26 – $29.65
- Volume
- 4.4M
- Avg. volume
- 2.11M
Price performance · TNDM
TNDM price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 13, 2026
TNDM closed at $20.07 after 20 trading sessions, up 22.53% for the selected period.
- Last close
- $20.07
- Period change
- +22.53%
- Period low
- $16.35
- Period high
- $20.07
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 13, 2026 | $19.002 | $20.26 | $18.53 | $20.07 | 4.4M |
| Nov 12, 2026 | $18.82 | $19.20 | $17.48 | $17.51 | 2.26M |
| Nov 11, 2026 | $18.65 | $19.76 | $18.46 | $18.77 | 2.56M |
| Nov 10, 2026 | $17.77 | $18.83 | $17.58 | $18.71 | 2.72M |
| Nov 9, 2026 | $16.56 | $18.28 | $16.54 | $18.17 | 2.64M |
| Nov 6, 2026 | $15.83 | $17.32 | $15.45 | $16.91 | 5.88M |
| Nov 5, 2026 | $18.925 | $19.57 | $17.625 | $17.99 | 3.03M |
| Nov 4, 2026 | $17.83 | $19.285 | $17.83 | $19.05 | 3.71M |
| Nov 3, 2026 | $18.67 | $18.67 | $17.61 | $17.65 | 2.57M |
| Nov 2, 2026 | $19.345 | $19.5948 | $18.42 | $18.67 | 2.9M |
| Oct 30, 2026 | $19.42 | $19.59 | $18.71 | $19.11 | 1.87M |
| Oct 29, 2026 | $19.71 | $20.25 | $19.46 | $19.79 | 3.36M |
| Oct 28, 2026 | $18.93 | $19.71 | $18.75 | $19.68 | 2.14M |
| Oct 27, 2026 | $18.725 | $19.25 | $18.18 | $19.22 | 2.06M |
| Oct 26, 2026 | $17.42 | $18.98 | $17.21 | $18.90 | 4.49M |
| Oct 23, 2026 | $17.06 | $17.56 | $16.89 | $17.43 | 1.82M |
| Oct 22, 2026 | $16.47 | $17.20 | $16.24 | $17.15 | 1.87M |
| Oct 21, 2026 | $16.60 | $16.95 | $16.12 | $16.35 | 1.53M |
| Oct 20, 2026 | $16.47 | $16.865 | $16.37 | $16.52 | 1.59M |
| Oct 19, 2026 | $16.23 | $16.5246 | $16.00 | $16.38 | 1.27M |
Latest TNDM news
The latest Smart Investors Daily articles mentioning TNDM.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TNDM research
Overview
Company profile and research snapshot.
Company profile
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $19.80
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 6, 2026 | Barclays | Equal-Weight | — |
| Nov 6, 2026 | Wells Fargo | Overweight | — |
| Oct 7, 2026 | Barclays | Equal-Weight | — |
| Sep 30, 2026 | Citigroup | Neutral | — |
| Sep 24, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Nov 10, 2026
TNDM Q3 2026 deep dive: business model transition, product launches, and leadership change
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 13.8% year on year to $283.7 million. The company expects the full year’s revenue to be around $1.08 billion, close to analysts’ estimates. Its GAAP loss of $0.10 per share was 59.6% above analysts’ consensus estimates.
Yahoo · Nov 7, 2026
Can Tandem Diabetes Care (TNDM) Justify Its Valuation As Q3 Earnings Beat And CEO Change Land?
Tandem Diabetes Care (TNDM) is back in focus after third quarter results showed higher sales, a much smaller net loss, reaffirmed full year revenue guidance, and a planned CEO transition to Jeannette Bankes. The latest Q3 update and the CEO transition have landed against a choppy backdrop for Tandem Diabetes Care’s stock. The share price fell 6.0% on the day to $16.91 and is down 11.5% over the past week, yet shows a 6.8% 1 month share price gain. The 1 year total shareholder return of 4.0%...
Yahoo · Nov 6, 2026
What Tandem Diabetes Care (TNDM) Said on Its Q3 Earnings Call
Tandem Diabetes Care (NASDAQ:TNDM) reported 14% revenue growth in the third quarter of 2026, as higher pump shipments, pharmacy pricing and international sales helped lift gross margin. The company also announced a CEO transition and signaled that a slower-than-expected shift to pharmacy distributio
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
